Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer

ClinicalTrials.gov ID: NCT01494506

Public ClinicalTrials.gov record NCT01494506. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study is an open label, randomized phase 3 study of MM-398 with or without 5-Fluorouracil (5-FU) and Leucovorin (also known as folinic acid), versus 5-FU and leucovorin in metastatic pancreatic cancer patients who have progressed on prior gemcitabine based therapy.

Study identification

NCT ID: NCT01494506
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Merrimack Pharmaceuticals; Industry
Enrollment: 417 participants

Conditions and interventions

Conditions

Metastatic Pancreatic Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2011 (Type not available)
Primary completion: Feb 2014 (Actual)
Completion: Oct 2015 (Actual)
Last update posted: Jun 17, 2016

2011 – 2015

United States locations

U.S. sites: 23
U.S. states: 13
U.S. cities: 23

Facility	City	State	ZIP	Site status
Not listed	Gilbert	Arizona	—	—
Not listed	Glendale	Arizona	—	—
Not listed	Scottsdale	Arizona	—	—
Not listed	Burbank	California	—	—
Not listed	Duarte	California	—	—
Not listed	Fresno	California	—	—
Not listed	LaVerne	California	—	—
Not listed	San Luis Obispo	California	—	—
Not listed	Boyton Beach	Florida	—	—
Not listed	Atlanta	Georgia	—	—
Not listed	Kansas City	Missouri	—	—
Not listed	St Louis	Missouri	—	—
Not listed	Henderson	Nevada	—	—
Not listed	Albuquerque	New Mexico	—	—
Not listed	Buffalo	New York	—	—
Not listed	Columbus	Ohio	—	—
Not listed	Norman	Oklahoma	—	—
Not listed	Greenville	South Carolina	—	—
Not listed	Bedford	Texas	—	—
Not listed	Dallas	Texas	—	—
Not listed	Tyler	Texas	—	—
Not listed	Fairfax	Virginia	—	—
Not listed	Norfolk	Virginia	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01494506, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 17, 2016 · Synced Oct 26, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01494506 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →